Hashimoto's thyroiditis
Conditions
Interventions
Group 1:treated with metformin,initial dosage: 0.5 g/day, gradually increased to 1.5 g/day within one month
Group 2:treated with other oral hypoglycemic drugs
Sponsors
University-Town Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1)All the patients included in the study met the diagnostic criteria for type 2 diabetes in the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 Edition) and WHO (1999). 1) Typical diabetic symptoms (polydipsia, polyuria, polyphoresis, unexplained weight loss) plus random blood glucose >=11.1 or plus 2) fasting blood glucose >=7.0 or plus 3) 2-hour blood glucose after glucose loading >=11.1, and in line with the diagnostic criteria for thyroiditis in the Chinese Guidelines for the Diagnosis and Treatment of Thyroid Diseases: The thyroid function is normal, but the titers of TPOAb and TgAb are significantly increased. (2) Age >= 18 years old and <=80 years old; (3) The patient gives informed consent and signs the informed consent form.
Exclusion criteria
Exclusion criteria: ?(1)? Current or prior history of comorbid thyroid disorders (e.g., thyrotoxicosis, hypothyroidism, thyroid nodules, thyroid tumors), thyroid surgery, or radiation exposure, which may cause thyroid hormone secretion abnormalities (e.g., hypopituitarism, prolactinoma); ?(2)? Acute diabetic complications, severe chronic diabetic complications, severe infections, trauma, surgery, malignancies, heart failure, acute myocardial infarction, hypotension, or oxygen deprivation; ?(3)? Pregnancy or lactation; severe cardiovascular disease; hepatic or renal insufficiency; untreated hypertension; or pulmonary insufficiency; ?(4)? Participation in other drug clinical trials within the past six months; ?(5)? Any other condition potentially interfering with intervention compliance or follow-up completion; ?(6)? Investigator-determined contraindications (e.g., diseases affecting outcome assessment or general unsuitability for enrollment).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The volume of the thyroid;Thyroid stimulating hormone;Free thyroxine;Free triiodothyronine;Thyroid globulin antibody;Thyroid peroxidase antibody ;Thyroid stimulating hormone receptor antibody ;Tumor necrosis factor-a;Interferon-?;Interleukin-2;Soluble Fas;Soluble Fas ligand ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Glycated hemoglobin;Total cholesterol;Triglycerides;Low-density lipoprotein ;High-density lipoprotein;Body mass index; | — |
Countries
China
Contacts
Public ContactChen Guangmin
University-Town Hospital of Chongqing Medical University
Outcome results
None listed